WAYNE, Pa. and MISGAV, Israel, April 15, 2014 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN) (LSE:MEDU) (LSE:MEDG), the developer of BioPump(TM) a novel technology for the sustained production and delivery of therapeutic proteins in patients using ex-vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced that its wholly owned subsidiary, Medgenics Medical Israel Ltd. (MMI), was awarded a government grant of up to NIS 7.7 million (approximately USD 2.2 million), from the Office of the Chief Scientist (OCS) at the Ministry of Economy of Israel.
Help employers find you! Check out all the jobs and post your resume.
